{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T14:51:36Z","timestamp":1775746296022,"version":"3.50.1"},"reference-count":57,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>Idiopathic pulmonary fibrosis (IPF) is a progressive fatal disease that up to now has been associated with a poor outcome. Some advances have been made in understanding the multiple interrelated pathogenic pathways underlying IPF. The disease is now believed to result from complex interactions among genetic, epigenetic, transcriptional, posttranscriptional, metabolic, and environmental factors. The discovery and validation of theranostic biomarkers are necessary to enable a more precise and earlier diagnosis of IPF and to improve the prediction of future disease behavior. Two drugs recently approved by the US Food and Drug Administration, pirfenidone and nintedanib, have shown the ability to reduce the progression of the disease, although survival benefits are only minimal and neither drug prevents or reverses the disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To provide a critical overview of the main experimental studies carried out for testing the principal effects of pirfenidone and nintedanib on IPF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources.\u2014<\/jats:title>\n                    <jats:p>Experimental (animal and in vitro) studies concerning both drugs were used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>Pirfenidone has a longer history of preclinical experimental studies than nintedanib. Many studies have been reported more recently (after 2014) and some of them evaluated the association of both drugs, thus suggesting their combination in future therapeutic approaches. Future investigations focusing on targets at molecular, cellular, and tissue levels are necessary to have a better in-depth knowledge of the properties of these drugs and to explore the potential efficacy of both or other drug combinations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2018-0080-ra","type":"journal-article","created":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T13:49:51Z","timestamp":1535118591000},"page":"1090-1097","source":"Crossref","is-referenced-by-count":7,"title":["Idiopathic Pulmonary Fibrosis and Antifibrotic Treatments: Focus on Experimental Studies"],"prefix":"10.5858","volume":"142","author":[{"given":"Francesca","family":"Lunardi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Pezzuto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania Edith","family":"Vuljan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiorella","family":"Calabrese","sequence":"additional","affiliation":[{"name":"From the Department of Cardiac, Thoracic and Vascular Sciences, University of Padova Medical School, Padova, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3906","reference":[{"issue":"9807","key":"2020081220432443800_i1543-2165-142-9-1090-b01","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(11)60052-4","article-title":"Idiopathic pulmonary fibrosis","volume":"378","author":"King","year":"2011","journal-title":"Lancet"},{"issue":"6","key":"2020081220432443800_i1543-2165-142-9-1090-b02","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"2020081220432443800_i1543-2165-142-9-1090-b03","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S2213-2600(17)30433-2","article-title":"Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society white paper","volume":"6","author":"Lynch","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"7","key":"2020081220432443800_i1543-2165-142-9-1090-b04","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S2213-2600(16)30033-9","article-title":"Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study","volume":"4","author":"Walsh","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"10","key":"2020081220432443800_i1543-2165-142-9-1090-b05","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1097\/PAS.0000000000000885","article-title":"Pathologic separation of chronic hypersensitivity pneumonitis from fibrotic connective tissue disease-associated interstitial lung disease","volume":"41","author":"Churg","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"2020081220432443800_i1543-2165-142-9-1090-b06","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/his.13443","article-title":"Cicatricial organising pneumonia mimicking a fibrosing interstitial pneumonia","volume":"72","author":"Churg","year":"2018","journal-title":"Histopathology"},{"issue":"22","key":"2020081220432443800_i1543-2165-142-9-1090-b07","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1401739","article-title":"Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis","volume":"370","author":"Idiopathic Pulmonary Fibrosis Clinical Research Network","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"2020081220432443800_i1543-2165-142-9-1090-b08","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1164\/rccm.201506-1063ST","article-title":"An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis: an update of the 2011 clinical practice guideline","volume":"192","author":"Raghu","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"2020081220432443800_i1543-2165-142-9-1090-b09","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/nrd.2017.170","article-title":"Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease","volume":"16","author":"Mora","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"2020081220432443800_i1543-2165-142-9-1090-b10","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1164\/rccm.200404-571OC","article-title":"Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"171","author":"Azuma","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"2020081220432443800_i1543-2165-142-9-1090-b11","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1183\/09031936.00005209","article-title":"Pirfenidone in idiopathic pulmonary fibrosis","volume":"35","author":"Taniguchi","year":"2010","journal-title":"Eur Respir J"},{"issue":"9779","key":"2020081220432443800_i1543-2165-142-9-1090-b12","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"issue":"22","key":"2020081220432443800_i1543-2165-142-9-1090-b13","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"issue":"12","key":"2020081220432443800_i1543-2165-142-9-1090-b14","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","article-title":"Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis","volume":"365","author":"Richeldi","year":"2011","journal-title":"N Engl J Med"},{"issue":"22","key":"2020081220432443800_i1543-2165-142-9-1090-b15","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"2020081220432443800_i1543-2165-142-9-1090-b16","doi-asserted-by":"crossref","first-page":"26385","DOI":"10.3402\/ecrj.v2.26385","article-title":"Pharmacological treatment of idiopathic pulmonary fibrosis - preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine","volume":"2","author":"Myll\u00e4rniemi","year":"2015","journal-title":"Eur Clin Respir J"},{"issue":"6","key":"2020081220432443800_i1543-2165-142-9-1090-b17","first-page":"779","article-title":"Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters","volume":"125","author":"Iyer","year":"1995","journal-title":"J Lab Clin Med"},{"issue":"1","key":"2020081220432443800_i1543-2165-142-9-1090-b18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0022-3565(24)38125-X","article-title":"Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis","volume":"289","author":"Iyer","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"2020081220432443800_i1543-2165-142-9-1090-b19","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0022-3565(24)35110-9","article-title":"Effects of pirfenidone on transforming growth factor-\u03b2 gene expression at the transcriprional level in bleomycin hamster model of lung fibrosis","volume":"291","author":"Iyer","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"2020081220432443800_i1543-2165-142-9-1090-b20","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1023\/A:1007068313370","article-title":"Anti-infiammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation","volume":"24","author":"Iyer","year":"2000","journal-title":"Inflammation"},{"issue":"2-3","key":"2020081220432443800_i1543-2165-142-9-1090-b21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0378-4274(96)03845-3","article-title":"Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice","volume":"90","author":"Kehrer","year":"1997","journal-title":"Toxicol Lett"},{"issue":"1","key":"2020081220432443800_i1543-2165-142-9-1090-b22","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/toxsci\/kfg167","article-title":"Differential effects of pirfenidone on acute pulmonary injury and ensuing fibrosis in the hamster model of amiodarone-induced pulmonary toxicity","volume":"75","author":"Card","year":"2003","journal-title":"Toxicol Sci"},{"issue":"1","key":"2020081220432443800_i1543-2165-142-9-1090-b23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1183\/09031936.04.00120803","article-title":"Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis","volume":"24","author":"Kakugawa","year":"2004","journal-title":"Eur Respir J"},{"issue":"3-4","key":"2020081220432443800_i1543-2165-142-9-1090-b24","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.lfs.2007.11.003","article-title":"Pirfenidone inhibits the expression of HSP47 in TGF-B1 stimulated human lung fibroblasts","volume":"82","author":"Nakayama","year":"2008","journal-title":"Life Sci"},{"key":"2020081220432443800_i1543-2165-142-9-1090-b25","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1471-2466-12-24","article-title":"Pirfenidone inhibits TGF-\u03b21-induced over-expression of collagen type I and heat shock protein 47 in A549 cells","volume":"12","author":"Hisatomi","year":"2012","journal-title":"BMC Pulm Med"},{"issue":"6","key":"2020081220432443800_i1543-2165-142-9-1090-b26","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/j.1600-6143.2005.00876.x","article-title":"Pirfenidone inhibits lung allograft fibrosis through L-arginine-arginase pathway","volume":"5","author":"Liu","year":"2005","journal-title":"Am J Transplant"},{"issue":"1-3","key":"2020081220432443800_i1543-2165-142-9-1090-b27","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ejphar.2008.06.046","article-title":"Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis","volume":"590","author":"Oku","year":"2008","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"2020081220432443800_i1543-2165-142-9-1090-b28","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3109\/15563650.2012.718783","article-title":"Effect of pirfenidone on pulmonary fibrosis due to paraquat poisoning in rats","volume":"50","author":"Seifirad","year":"2012","journal-title":"Clin Toxicol (Phila)"},{"issue":"5","key":"2020081220432443800_i1543-2165-142-9-1090-b29","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.3892\/etm.2013.1308","article-title":"Inhibition of fibrosis and inflammation by triple therapy with pirfenidone, edaravone and erythropoietin in rabbits with drug-induced lung injury: comparison of CT imaging and pathological findings","volume":"6","author":"Watanabe","year":"2013","journal-title":"Exp Ther Med"},{"issue":"5","key":"2020081220432443800_i1543-2165-142-9-1090-b30","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1183\/09031936.00152106","article-title":"Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis","volume":"29","author":"Chaudhary","year":"2007","journal-title":"Eur Respir J"},{"issue":"12","key":"2020081220432443800_i1543-2165-142-9-1090-b31","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1158\/1535-7163.MCT-06-0323","article-title":"Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors","volume":"5","author":"Kulimova","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"2020081220432443800_i1543-2165-142-9-1090-b32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejps.2014.02.014","article-title":"Effect of pirfenidone on proliferation, TGF-\u03b2-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts","volume":"58","author":"Conte","year":"2014","journal-title":"Eur J Pharm Sci"},{"issue":"1-2","key":"2020081220432443800_i1543-2165-142-9-1090-b33","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ijpharm.2014.03.003","article-title":"Cell viability of fibroblasts to pifenidone and sirolimus: a future concept for drug eluting stents","volume":"466","author":"Walter","year":"2014","journal-title":"Int J Pharm"},{"key":"2020081220432443800_i1543-2165-142-9-1090-b34","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1465-9921-15-16","article-title":"Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis","volume":"15","author":"Inomata","year":"2014","journal-title":"Respir Res"},{"issue":"2","key":"2020081220432443800_i1543-2165-142-9-1090-b35","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1165\/rcmb.2013-0310OC","article-title":"A novel genomic signature with translational significance for human idiopathic pulmonary fibrosis","volume":"52","author":"Bauer","year":"2015","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2020081220432443800_i1543-2165-142-9-1090-b36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pupt.2016.05.003","article-title":"Pirfenidone inhibits p38-mediated generation of procoagulant microparticles by human alveolar epithelial cells","volume":"39","author":"Neri","year":"2016","journal-title":"Pulm Pharmacol Ther"},{"issue":"1","key":"2020081220432443800_i1543-2165-142-9-1090-b37","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12890-017-0405-7","article-title":"Pirfenidone attenuates bleomycin-induced pulmonary fibrosis in mice by regulating Nrf2\/Bach1 equilibrium","volume":"17","author":"Liu","year":"2017","journal-title":"BMC Pulm Med"},{"issue":"1","key":"2020081220432443800_i1543-2165-142-9-1090-b38","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12931-016-0418-4","article-title":"Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis","volume":"17","author":"Xie","year":"2016","journal-title":"Respir Res"},{"issue":"1","key":"2020081220432443800_i1543-2165-142-9-1090-b39","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1080\/13880209.2016.1247879","article-title":"Effects and mechanisms of pirfenidone, prednisone and acetylcysteine on pulmonary fibrosis in rat idiopathic pulmonary fibrosis models","volume":"55","author":"Yu","year":"2017","journal-title":"Pharm Biol"},{"issue":"5","key":"2020081220432443800_i1543-2165-142-9-1090-b40","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1096\/fj.201600892RR","article-title":"Pirfenidone exerts antifibrotic effects through inhibition of GLI transcription factors","volume":"31","author":"Didiasova","year":"2017","journal-title":"FASEB J"},{"issue":"1","key":"2020081220432443800_i1543-2165-142-9-1090-b41","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12931-017-0600-3","article-title":"Pirfenidoneinhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy","volume":"18","author":"Kurita","year":"2017","journal-title":"Respir Res"},{"key":"2020081220432443800_i1543-2165-142-9-1090-b42","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.fct.2017.12.034","article-title":"Pirfenidone protects against paraquat-induced lung injury and fibrosis in mice by modulation of inflammation, oxidative stress, and gene expression","volume":"112","author":"Pourgholamhossein","year":"2017","journal-title":"Food Chem Toxicol"},{"issue":"1","key":"2020081220432443800_i1543-2165-142-9-1090-b43","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s10753-017-0671-9","article-title":"Combination therapy with pirfenidone plus prednisolone ameliorates paraquat-induced pulmonary fibrosis","volume":"41","author":"Rasooli","year":"2018","journal-title":"Inflammation"},{"issue":"2","key":"2020081220432443800_i1543-2165-142-9-1090-b44","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1124\/jpet.113.208223","article-title":"Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis","volume":"349","author":"Wollin","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"2020081220432443800_i1543-2165-142-9-1090-b45","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12931-014-0157-3","article-title":"Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis","volume":"15","author":"Hostettler","year":"2014","journal-title":"Respir Res"},{"key":"2020081220432443800_i1543-2165-142-9-1090-b46","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.pupt.2015.03.001","article-title":"Nintedanib modulates surfactant protein-D expression in A549 human lung epithelial cells via the c-Jun N-terminal kinase-activator protein-1 pathway","volume":"32","author":"Kamio","year":"2015","journal-title":"Pulm Pharmacol Ther"},{"issue":"3","key":"2020081220432443800_i1543-2165-142-9-1090-b47","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10456-017-9543-z","article-title":"Effects of nintedanib on the microvascular architecture in a lung fibrosis model","volume":"20","author":"Ackermann","year":"2017","journal-title":"Angiogenesis"},{"issue":"1","key":"2020081220432443800_i1543-2165-142-9-1090-b48","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1165\/rcmb.2014-0445OC","article-title":"Novel mechanisms for the anti-fibrotic action of nintedanib","volume":"54","author":"Rangarajan","year":"2016","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"1","key":"2020081220432443800_i1543-2165-142-9-1090-b49","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12931-017-0654-2","article-title":"Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity","volume":"18","author":"Sato","year":"2017","journal-title":"Respir Res"},{"issue":"11","key":"2020081220432443800_i1543-2165-142-9-1090-b50","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1111\/jcmm.13206","article-title":"Nintedanibreduces ventilation-augmented bleomycin-induced epithelial-mesenchymal transition and lung fibrosis through suppression of the Src pathway","volume":"21","author":"Li","year":"2017","journal-title":"J Cell Mol Med"},{"issue":"4","key":"2020081220432443800_i1543-2165-142-9-1090-b51","doi-asserted-by":"crossref","first-page":"e00030","DOI":"10.1002\/prp2.30","article-title":"Assessment of the effect of potential antifibrotic compounds on total and \u03b1V\u03b26 integrin-mediated TGF-\u03b2 activation","volume":"2","author":"Porte","year":"2014","journal-title":"Pharmacol Res Perspect"},{"issue":"4","key":"2020081220432443800_i1543-2165-142-9-1090-b52","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1164\/rccm.201412-2233OC","article-title":"FK506-binding protein 10, a potential novel drug target for idiopathic pulmonary fibrosis","volume":"192","author":"Staab-Weijnitz","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2020081220432443800_i1543-2165-142-9-1090-b53","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12931-016-0328-5","article-title":"Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis","volume":"17","author":"Lehtonen","year":"2016","journal-title":"Respir Res"},{"issue":"1","key":"2020081220432443800_i1543-2165-142-9-1090-b54","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1165\/rcmb.2016-0217OC","article-title":"A novel antifibrotic mechanism of nintedanib and pirfenidone: inhibition of collagen fibril assembly","volume":"57","author":"Kn\u00fcppel","year":"2017","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"7","key":"2020081220432443800_i1543-2165-142-9-1090-b55","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.bbadis.2013.01.018","article-title":"Strategies for biomarker discovery in fibrotic disease","volume":"1832","author":"Marshall","year":"2013","journal-title":"Biochim Biophys Acta"},{"issue":"7","key":"2020081220432443800_i1543-2165-142-9-1090-b56","first-page":"661","article-title":"Idiopathic pulmonary fibrosis: are any of the morphological-molecular markers useful in clinical management?","volume":"32","author":"Lunardi","year":"2017","journal-title":"Histol Histopathol"},{"issue":"5","key":"2020081220432443800_i1543-2165-142-9-1090-b57","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1165\/rcmb.2017-0096ST","article-title":"An official American Thoracic Society Workshop Report: Use of Animal Models for the Preclinical Assessment of Potential Therapies for Pulmonary Fibrosis","volume":"56","author":"Jenkins","year":"2017","journal-title":"Am J Respir Cell Mol Biol"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/142\/9\/1090\/1449178\/arpa_2018-0080-ra.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/142\/9\/1090\/1449178\/arpa_2018-0080-ra.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:34:03Z","timestamp":1764790443000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/142\/9\/article-p1090.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,1]]},"references-count":57,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2018-0080-ra","relation":{},"ISSN":["0003-9985","1543-2165"],"issn-type":[{"value":"0003-9985","type":"print"},{"value":"1543-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,1]]}}}